オハイオにおける膠腫の臨床試験
オハイオ内の拠点で、膠腫に関する18件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- 他3件
被験者募集中第1/2相
12 Months – 21 Years · 全性別 · 2026/10/01更新 · NCT05099003Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Cleveland Clinic Taussig Cancer Center, Cleveland
- Ohio State University, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07326566ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Cincinnati Children's Hospital, Cincinnati
- Nationwide Children's Hospital, Columbus
被験者募集中第2相
12 Months – 39 Years · 全性別 · 2026/09/21更新 · NCT06838676Development of MRF for Characterization of Brain Tumors After Radiotherapy
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland
- Cleveland Clinic Taussig Cancer Center, Cleveland
被験者募集中健康なボランティア歓迎
18歳〜60歳 · 全性別 · 2026/09/15更新 · NCT06101069Targeted Pediatric High-Grade Glioma Therapy
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
被験者募集中観察研究
12 Months – 39 Years · 全性別 · 2026/09/08更新 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
被験者募集中第2相
12歳〜39歳 · 全性別 · 2026/09/01更新 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Cleveland Clinic, Cleveland
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
被験者募集中第2相
3歳〜39歳 · 全性別 · 2026/08/24更新 · NCT05096481Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/06更新 · NCT05565118A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Nationwide Children's Hospital, Colombus
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
- Taylor Cancer Research Center, Maumee
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
- Ohio State University Medical Center, Columbus
被験者募集中
18歳〜85歳 · 全性別 · 2026/07/21更新 · NCT06910306Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
被験者募集中第1/2相
4歳〜39歳 · 全性別 · 2026/07/20更新 · NCT05278208Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
被験者募集中早期第1相健康なボランティア歓迎
1歳〜21歳 · 全性別 · 2026/06/29更新 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
被験者募集中第2相
12 Months – 39 Years · 全性別 · 2026/05/29更新 · NCT05843253Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/08更新 · NCT06964737Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT06810544A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
被験者募集中早期第1相
21歳以下 · 全性別 · 2026/03/18更新 · NCT04655404Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
- Nationwide Children's Hospital, Columbus
被験者募集中第1相
12 Months – 39 Years · 全性別 · 2025/05/13更新 · NCT04254419ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。